Trials / Recruiting
RecruitingNCT07081646
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 91 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD0120 | Participants will receive AZD0120 via intravenous (IV) infusion. |
Timeline
- Start date
- 2025-08-18
- Primary completion
- 2029-08-15
- Completion
- 2031-02-14
- First posted
- 2025-07-23
- Last updated
- 2026-03-24
Locations
18 sites across 3 countries: United States, Canada, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07081646. Inclusion in this directory is not an endorsement.